Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

COSCIENS Biopharma Inc T.AEZS

COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources used in cosmeceutical products (i.e., oat beta glucan and avenanthramides, which are found in skincare product brands like Aveeno and Burt’s Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals.


TSX:AEZS - Post by User

Comment by prophetoffactzon Jun 27, 2024 2:02pm
74 Views
Post# 36109339

RE:RE:RE:RE:I'm concerned .

RE:RE:RE:RE:I'm concerned .Microcap biotech is very high risk. Most projects fail and/or take longer than expected resulting in dilution. There is a significant upfront burn rate before revenue is often realized increasing risk. Capitalism is highly competitive and someone is always trying to do things better. CZO's revenue generating products have also depended on consumer preferences and those can change quickly. You need broad diversification to play risk like this. If you put any more than 1-2% of your portfolio in a company like this or whatever you can't afford to lose you are playing with fire. The stock has shot up to as high as $2.50 allowing investors to cash out their investment in the past, make a big return, and let the rest ride. Even general macro risk can sink biotech. We've been through the worst biotech bear market in history due to a four decade high inflation shock from a 1-in-100 year pandemic. Just because you are an insider doesn't mean you can escape such macro risk which has nothing to do with the company. We've also seen a major client of CZO's change its ordering which has nothing to do with the company. CZO's major client came under new management as a result of a spin-off. Unforseen events like that happen. Given the overwhelming risk microcap biotech companies are more often than not sunk by factors other than the insiders. Just because you are an insider doesn't solve for the vast majority of risks. Gilles has never sold a single share and only added to his holdings over time. He's dedicated the most important years of his career to this company. The Canadian government has provided material funding after review. The company has chosen to invest its profits in these long-term projects and insiders won't make money off the options if the projects don't pay off. Other Directors with shares left after shareholders votes.

The holdings of insiders is what it is. If they had invested in CZO at $.70 would that have made them better; especially if they are at retirement age and can't afford to lose? The overwhelming risk of microcap hit CZO. If anyone doesn't value the time of insiders, what has been invested, and isider resumes, and the support of the Canada's government, and the results achieved to date they don't have to invest. We all must make a tough decision.     


jrsloan60 wrote: Why does market think differently.I have 200,000.00 in. I did think PGX was a good idea as well as a pharmaceutical grade plant. My point is how can you sell it to the market when you can't get existed shareholders to buy in and it doesn't look like the ownership or the leadership has bought in like putting some of their money in the game . How much cash has any of the board members put into this company of their own money?


<< Previous
Bullboard Posts
Next >>

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse